Task: Answer Verification
Input (English): Question: Does anti-IGF-1R monoclonal antibody inhibit the carcinogenicity activity of acquired trastuzumab-resistant SKOV3?
Answer: We achieved satisfactory anti-tumor activity using trastuzumab plus LMAb1 in trastuzumab-resistant ovarian cancer model. In similar cases, not only acquired but also de novo, good curative effect might be achieved using combined antibody therapy strategies.
Output (English): yes